Summary
Carboplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Thyroid Cancer (Well-Differentiated) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Thyroid Cancer (Well-Differentiated). ClinicalTrials.gov lists 4 registered trials linking Carboplatin to Thyroid Cancer (Well-Differentiated): 1 is active or not yet recruiting; 1 has completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT01701349). The largest enrolment is 80 participants (NCT00507429). Registration activity spans 1999 to 2024. The literature layer holds 1 publication for this pair: 1 clinical trial publication. The dated items are from 2014. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Thyroid Cancer ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not applicable — surgical resection is standard; papillary microcarcinoma (<1 cm, low-risk): active surveillance achieves 99.8%+ cancer-specific survival at 10 years without immediate surgery in Japanese cohorts.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 31.0 (trials 9.0, literature 2.0, tier 15, approved bonus 5.0) |
| Registered trials | 4 total: 0 recruiting, 1 active / not yet recruiting, 1 completed, 2 other |
| Linked publications | 1 (1 clinical trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | EGFR |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer 2015 | withdrawn | Phase 3 | — |
| NCT06713057 | Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer 2024 | not yet recruiting | Phase 2 | 20 |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu 1999 | completed | Phase 1 | 15 |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer 2007 | terminated | PHASE2, PHASE3 | 80 |
Published literature
- Clinical trial publication Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinomaSosa JA, Elisei R, Jarzab B et al. · Thyroid : official journal of the American Thyroid Association · 2014 · PMID 23721245
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target EGFR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Carboplatin approved for Thyroid Cancer (Well-Differentiated)?
Carboplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Thyroid Cancer (Well-Differentiated) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Thyroid Cancer (Well-Differentiated). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Carboplatin in clinical trials for Thyroid Cancer (Well-Differentiated)?
ClinicalTrials.gov lists 4 registered trials linking Carboplatin to Thyroid Cancer (Well-Differentiated): 1 is active or not yet recruiting; 1 has completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT01701349). The largest enrolment is 80 participants (NCT00507429). Registration activity spans 1999 to 2024.
What does the evidence show for Carboplatin in Thyroid Cancer (Well-Differentiated)?
Carboplatin has 1 completed trial and 1 linked publication for Thyroid Cancer (Well-Differentiated). Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target EGFR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.